Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Advances in Gastroenterology and Hepatology
This week's episode covers recent advances in NAFLD treatment, Crohn's disease management strategies, and the therapeutic potential of fecal microbiota transplantation.
Bibliography
1. Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis.
Authors: Li S, Duan F, Li S, et al.
Journal: Annals of hepatology, 2024 Mar-Apr
PMID: 38579127
DOI: 10.1016/j.aohep.2023.101174
2. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Authors: Noor NM, Lee JC, Bond S, et al.
Journal: The lancet. Gastroenterology & hepatology, 2024 May
PMID: 38402895
DOI: 10.1016/S2468-1253(24)00034-7
3. Fecal microbiota transplantation: current challenges and future landscapes.
Authors: Yadegar A, Bar-Yoseph H, Monaghan TM, et al.
Journal: Clinical microbiology reviews, 2024 Jun 13
PMID: 38717124
DOI: 10.1128/cmr.00060-22
4. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
5. Long-term safety of vedolizumab for inflammatory bowel disease.
Authors: Loftus EV Jr, Feagan BG, Panaccione R, et al.
Journal: Alimentary pharmacology & therapeutics, 2020 Oct
PMID: 32876349
DOI: 10.1111/apt.16060
6. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Authors: Feagan BG, Sandborn WJ, Gasink C, et al.
Journal: The New England journal of medicine, 2016 Nov 17
PMID: 27959607
DOI: 10.1056/NEJMoa1602773
7. Biomimetic materials for medical applications.
Authors: Zhang Y, Guo J, Luo Q, et al.
Journal: Chinese medical journal, 2026 May 20
PMID: 41906208
DOI: 10.1097/CM9.0000000000004036
8. Artificial intelligence and capsule endoscopy.
Authors: Casanova Rimer G, Urpí Ferreruela M, Bretto E, et al.
Journal: Revista espanola de enfermedades digestivas, 2026 May
PMID: 41848084
DOI: 10.17235/reed.2026.11191/2025
9. Understanding the gut microbiota and sarcopenia: a systematic review.
Authors: Liu C, Cheung WH, Li J, et al.
Journal: Journal of cachexia, sarcopenia and muscle, 2021 Dec
PMID: 34523250
DOI: 10.1002/jcsm.12784
10. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
Authors: Li S, Duan F, Li S, et al.
Journal: Annals of hepatology, 2024 Mar-Apr
PMID: 38579127
DOI: 10.1016/j.aohep.2023.101174
2. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Authors: Noor NM, Lee JC, Bond S, et al.
Journal: The lancet. Gastroenterology & hepatology, 2024 May
PMID: 38402895
DOI: 10.1016/S2468-1253(24)00034-7
3. Fecal microbiota transplantation: current challenges and future landscapes.
Authors: Yadegar A, Bar-Yoseph H, Monaghan TM, et al.
Journal: Clinical microbiology reviews, 2024 Jun 13
PMID: 38717124
DOI: 10.1128/cmr.00060-22
4. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
5. Long-term safety of vedolizumab for inflammatory bowel disease.
Authors: Loftus EV Jr, Feagan BG, Panaccione R, et al.
Journal: Alimentary pharmacology & therapeutics, 2020 Oct
PMID: 32876349
DOI: 10.1111/apt.16060
6. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Authors: Feagan BG, Sandborn WJ, Gasink C, et al.
Journal: The New England journal of medicine, 2016 Nov 17
PMID: 27959607
DOI: 10.1056/NEJMoa1602773
7. Biomimetic materials for medical applications.
Authors: Zhang Y, Guo J, Luo Q, et al.
Journal: Chinese medical journal, 2026 May 20
PMID: 41906208
DOI: 10.1097/CM9.0000000000004036
8. Artificial intelligence and capsule endoscopy.
Authors: Casanova Rimer G, Urpí Ferreruela M, Bretto E, et al.
Journal: Revista espanola de enfermedades digestivas, 2026 May
PMID: 41848084
DOI: 10.17235/reed.2026.11191/2025
9. Understanding the gut microbiota and sarcopenia: a systematic review.
Authors: Liu C, Cheung WH, Li J, et al.
Journal: Journal of cachexia, sarcopenia and muscle, 2021 Dec
PMID: 34523250
DOI: 10.1002/jcsm.12784
10. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
